Health Professional Radio - Podcast

Returned guest, Ken Cahill, CEO of SilverCloud Health, a digital mental health platform, discusses a new employee mental health survey of 1,288 US-based individuals that examined employees’ mental health, wellbeing, and attitudes toward employer-sponsored mental health services and digitally delivered care. Data shows that many are struggling due to increased stress related to the COVID-19 pandemic. Ken Cahill is the CEO and co-founder of SilverCloud Health with offices in Boston, Dublin, and London. SilverCloud is the world’s leading digital mental health platform. It enables the delivery of clinically validated digital therapeutic care programs that are proven to significantly improve clinical outcomes, and increase access and scale while reducing care delivery costs. Prior to founding SilverCloud Health, Ken held senior positions in several multinational companies including, Dell, HP, and Gateway. Ken recently received the 2018 MedTech Boston 40 under 40 award and holds a BSc. degree in computing, a dip

Milton, a 68-year-old from Beulah, AL shares his experience of becoming 98 percent cancer free after his participation in a clinical trial for a recently FDA-approved CAR T cell therapy called BREYANZI® (lisocabtagene maraleucel) from Bristol-Myers Squibb. He was treated for a diffuse large B-cell lymphoma (DLBCL) – one of the most common types of non-Hodgkin’s lymphoma. Retired contractor-turned pastor, Auburn University sports fanatic and family man, Milton, was diagnosed with diffuse large B-cell lymphoma (DLBCL) – one of the most common types of non-Hodgkin’s lymphoma – in 2015. After failed chemotherapy, Milton enrolled in a clinical trial for the FDA approved CAR T cell therapy treatment called Breyanzi and a month later, was 98 percent cancer free. For Milton, it was his faith – including his faith in his treatment and care team – along with a strong family support system and winning attitude that helped him manage life since diagnosis: "You’ve got to have a belief system bigger than yourself; believe

Maya Said shares her personal story and how she came to co-found the Outcomes4Me free app to help simplify the process and improve outcomes for breast cancer patients and survivors. It connects patients to a platform that leverages AI and machine learning to analyze and consolidate medical records – regardless of provider, network, or geography – to gain access to clinical trials, approved treatments, and tools for symptom management. They have recently announced a partnership with Vanderbilt-Ingram Cancer Center to pilot a first-of-a-kind integrated survivorship platform for breast and prostate cancer patients. She talks about the uphill battle cancer patients are facing due to COVID-19 including delayed screenings and essential appointments and why now, more than ever, there needs to be a single source of truth to ensure patients are staying on top of their treatment plans. Maya spent the last 15 years working in healthcare, primarily in the pharmaceutical industry with a focus on increasing innovation and

Award-winning physician, Dr. Jill Rabin, Professor of Obstetrics and Gynecology at the Zucker School of Medicine at Hofstra Northwell discusses the recent book that she co-wrote with Gail Stein and Danielle O'Shaughnessy, called "MIND OVER BLADDER: A Step-By-Step Guide To Achieving Continence" (Morgan James, Dec 2020). This book seeks to educate women of all ages on the many causes of incontinence and the variety of treatment options available. Jill Maura Rabin, an award-winning physician, is a Professor of Obstetrics and Gynecology at the Zucker School of Medicine at Hofstra Northwell, Vice Chair for Education and Development at North Shore University Hospital and LIJ Medical Center/Northwell Health, Co-Chief of Ambulatory Care in OBGYN/Northwell Health, and Section Head of Urogynecology at LIJ/Northwell. Dr. Rabin, a Diplomate of the American Board of Obstetrics and Gynecology, is an active researcher, consultant, lecturer, and media spokesperson. She holds eight patents and one copyright for urogynecol

Dr. Vicki Goodman, VP, Therapeutic Area Head, Late Stage Oncology at Merck discusses the recent Phase 3 KEYNOTE-204 positive EU CHMP opinion for expanded approval of KEYTRUDA® (pembrolizumab) for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL) that meet certain criteria. Vicki Goodman, MD, is Vice President, Therapeutic Area Head for Late Stage Oncology at Merck. In this role, she oversees Merck’s portfolio in lung cancers, women’s cancers, hematology, and head and neck cancer. Vicki joined Merck from Bristol-Myers Squibb where most recently she was VP, Head, Clinical Development Center of Excellence. She is a hematologist and medical oncologist with 15 years of drug development experience in both government and industry. Vicki trained in internal medicine and hematology/oncology at the University of Michigan. She then served as a medical officer at FDA for over two years and subsequently worked at GlaxoSmithKline for eight years. While at GSK, Vicki took on roles of increasing re

Geneticist, Dr. Jennifer Ibrahim, MD, Head of North America Medical Affairs, Rare Disease at Sanofi Genzyme discusses rare genetic disease, why it's so hard to diagnose, and the important role of genetic counselors for families who had a history of a rare genetic disease or learn of it. She talks about some new technologies and tests that are helping diagnose rare genetic diseases and what she anticipates will improve diagnosis and treatment moving forward. Jennifer Ibrahim received her medical degree from New Jersey Medical School, trained in Pediatrics at Babies’ Hospital-Columbia University, and competed fellowship training in Human Genetics at the Mount Sinai School of Medicine. She practiced general, prenatal, metabolic, and cancer genetics in northern New Jersey and was a consultant to the state Newborn Screening Program. She joined Sanofi Genzyme in 2013 as the US Medical Director for Gaucher disease and MPS I, and has been in her current role as Head of Rare Medical for North America since 2018.

Dr. Nick Medendorp, CEO of UV Innovators discusses NuvaWave, the world's first UV handheld to demonstrate killing more than 99.9% of the live COVID virus in just one second. He talks about the challenges of disinfection today, the value of UV light disinfection in fighting dangerous pathogens, and his mission to help businesses during these challenging times. Dr. Nick Medendorp, Co-Founder & Chief Medical Officer. Nick is a seasoned CEO, technology, and product development leader with more than 115 US patents in medical devices, electronic materials, LED and lighting products. Nick was an executive at Cree Lighting as it grew from $36k to ~$1B. Nick has 25+ years of experience commercializing photonic technology. He earned his BS, MS, and PhD in Materials Engineering from Purdue University.

Ed Tracy, an award-winning broadcast veteran, writer, and editor discusses his new book "Gorilla In The Room And Other Stories" (Feb 2021) which started coming together while battling stage 3 colon cancer. Ed Tracy is an award-winning broadcast veteran, writer, editor, theater critic and host of “Conversations with Ed Tracy,” a Chicago-based cultural series of thoughtful and engaging discussions with authors, performing artists, and other arts-based leaders. Tracy was the founding executive director, and later president and CEO, of the Pritzker Military Library in Chicago that received the 2009 National Medal for Museum and Library Services and was recognized five times by the Webby Awards for outstanding programming, including “Pritzker Military Presents” and “Medal of Honor with Ed Tracy.” A recipient of a Chicago Midwest Regional Emmy Award and the Norwich University Board of Fellows Service Medallion, Tracy is a graduate of the University of Vermont with a bachelor of arts degree in theater and communi

Returned guest, Bruce Boise, author of the book "Cold Comfort: One Man's Struggle to Stop the Illegal Marketing of Powerful Opioid Drugs and Save Lives" discusses the recent 8.3 billion dollar Purdue Pharma Opioid settlement. Bruce Boise worked for nearly 24 years in the pharmaceutical industry, first as a hospital representative, and then as a sales manager in the Great Lakes region. After losing his job as a whistleblower, he spent portions of the next 17 years working with the United States Justice Department on two separate False Claims Act cases against his former employer, Cephalon/Teva, a neuro bio-tech company. His story is told in a new book, Cold Comfort: One Man's Struggle to Stop the Illegal Marketing of Powerful Opioid Drugs and Save Lives. He was featured on CBS-TV’s Whistleblower. Boise, after exposing how Cephalon was illegally marketing off-label prescription drug usage, waited many years to see justice after wearing a wire, losing his job, becoming homeless, and black-balled by the pharmace

Allison London Brown, CEO of UVision360, Inc. in North Carolina, discusses the Luminelle DTx Hysteroscopy System. Traditionally, these procedures are conducted in a hospital or ambulatory setting. But the Luminelle system is compact and designed to be used in the doctor's office, and the company is expected to file an application with the FDA that will allow doctors to conduct the first visual hysteroscope biopsy outside a hospital setting. This technology will help to fill an unmet medical need brought on by the COVID pandemic. Allison London Brown has 20+ years of diverse medical device, consumer and pharmaceutical experience in Healthcare. During her career, she has launched over 90 products/services, and has served as an advisor to CEOs, Corporate Boards, NGO’s, non-profits, and government organizations. She has led product pipeline, strategy, and fundraising initiatives for these organizations. Ms. London Brown leads UVision 360, Inc., focused on development of the LUMINELLE DTx Hysteroscopy System, a n

Dr. Mark Allen, MD, co-founder and CEO of Elevian, developer of therapies to treat age-related diseases like stroke and diabetes, discusses the drug candidate, recombinant growth differentiation factor 11 (rGDF11) with broad therapeutic benefits demonstrated in numerous animal studies. "Science" recognized GDF11 as a top scientific breakthrough calling it “the rejuvenation factor”. Dr. Mark Allen is the co-founder and chief executive officer at Elevian. Dr. Allen has a BS in Applied Physics from Columbia University and an MD from UCLA. During his medical training, he developed one of the first web-based clinical decision support systems to guide ER physicians to make the right patient care decisions. After clinical trials demonstrating significant improvements in healthcare quality and cost, Dr. Allen founded Corticon to bring this new technology to market. Under Dr. Allen’s leadership as CEO, Corticon became one of the leading commercial rules engine software products, powering automated decision-making in

Returned guest, Dr. Maria Milla, MD, Section Chief, Nicklaus Children's Pediatric Care Centers discusses the talk of the increase in childhood obesity due to increased anxiety and physical inactivity in children during the pandemic. Obesity leads to many chronic problems later in life including type 2 diabetes and hypertension and she talks about how providers can discuss the health impacts with parents. Dr. Maria Milla, MD, MPH, FAAP, is a pediatrician and serves as the section chief of Nicklaus Children’s Pediatric Care Centers. She earned her medical degree from the American University of the Caribbean on St. Maarten. Dr. Milla then completed a residency in pediatrics at MedStar Georgetown University Hospital in Washington, D.C. She also holds a Master of Public Health from Florida International University’s Robert Stempel College of Public Health & Social Work in Miami. Her clinical interests include general pediatric primary care, evidence-based medical education and early childhood literacy. Dr. Mi

Dr. Melanie Dean, Ph.D., psychologist, discusses her new book " The Hidden Power of Emotions: How to Activate Your Energy Field and Transform Your Life", a culmination of 10 years of research in psychology, molecular physics, and quantum physics. She has discovered that there is a science-backed system for tapping your intuition’s power and using it to get what you want. Melanie Dean, Ph.D. – is a psychologist with a background in science and business who has spent her career helping people work with their thoughts and feelings to achieve their own personal goals.  After 15 years building a publishing company for psychologists and psychiatrists, Dr. Dean went on to sell the company for the exact amount of money she had been envisioning and meditating on. Dr. Dean holds two patents on assessment systems that help physicians diagnose and treat chronic conditions and is author of Borderline Personality Disorder: The Latest Assessment and Treatment Strategies. While on faculty at the University of Missouri, Ka

Dr. Leigh Peterson, Ph.D., Vice President of Product Development at United Therapeutics discusses data published in the "New England Journal of Medicine" (Jan 2021) on the INCREASE study evaluating Tyvaso in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The INCREASE study is the first to demonstrate a clear benefit in patients with PH-ILD, a life-threatening disease with no currently FDA-approved treatments. She talks about what's next for Tyvaso as they look to achieve FDA approval. Leigh Peterson: In her role as Vice President, Product Development, Dr. Peterson is responsible for coordinating and managing all aspects of preclinical and clinical development of United Therapeutics’ products. Dr. Peterson joined United Therapeutics in 2008 as a Senior Clinical Research Scientist and was promoted to her current role as Vice President of Product Development in March 2017. Dr. Peterson received a BS in Biochemistry from the University of Wyoming, a PhD in Molecular Biology - Human G

John Orwin, President and CEO of Atreca, a biopharmaceutical company, discusses their drug Discovery Platform and how they are thinking differently about the fight against cancer and their part in helping to fuel the next generation of antibody-based advancements in cancer treatment. He also talks about what’s on the horizon in 2021 for Atreca’s lead candidate ATRC-101 and their additional pipeline developments. John Orwin, President and CEO of Atreca. John Orwin has more than 25 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer, Genentech, and most recently Relypsa. During Mr. Orwin’s tenure at Relypsa, the company launched and commercialized its lead candidate, Patiromer (US brand name Veltassa®), and was acquired by Galenica (ViforPharma) in a transaction worth over $1.5 billion. Prior to Relypsa, he served as Chief Executive Off

Colon cancer is the second deadliest cancer impacting both men and women, but it’s considered preventable if caught in earlier stages when it is most treatable. As the pandemic continues, it’s important that people stay up-to-date with their screenings and are aware of the options available, including tests that can be taken from home. Boston resident and colon cancer survivor Paul joins us today to discuss his colon cancer journey, including his experience with an at-home screening test, and the importance of early detection and choice in screening options. Paul, a Boston resident, took a positive at-home test result last year at age 52 and was diagnosed with stage 3 colorectal cancer through a follow up colonoscopy; he went through chemo this year during COVID and now considers himself a screening advocate.

Dr. Patricia Whitley-Williams, President of the National Foundation for Infectious Diseases (NFID) discusses the persistent gaps and racial disparities in vaccination coverage. She talks about the new NFID survey findings and explains the urgent need to encourage individuals to get vaccinated against both flu and COVID-19. Patricia N. Whitley-Williams, MD, is president of the National Foundation for Infectious Diseases (NFID) and is professor of pediatrics; chief of the Division of Pediatric Allergy, Immunology, and Infectious Diseases; and associate dean of inclusion and diversity at Rutgers Robert Wood Johnson Medical School. A native of Boston, she received a bachelor of science degree in biology from Simmons College in Boston and a medical degree from Johns Hopkins University School of Medicine. She completed her pediatric residency at Children’s Hospital Medical Center in Cincinnati and fellowship training in pediatric infectious diseases at Boston City Hospital/Boston University School of Medicine.She

Rebecca Seidel, President of the Cardiac Ablation Solutions Operating Unit at Medtronic, discusses the FDA approval of the DiamondTemp™ Ablation (DTA) system for the treatment of patients with atrial fibrillation. This is the first FDA approved, temperature controlled, irrigated radio frequency (RF) ablation system currently available to deliver ablations. Rebecca is President of the Cardiac Ablation Solutions Operating Unit (OU). Previously, she served as Vice President and GM of the Infection Control business where she led the integration and global expansion of that business. Over Rebecca’s 17-year career with Medtronic, she has held roles in Commercialization, Strategy, Product Support, Core Team Leadership, Field Service, and Product Marketing. She earned the Wallin Leadership Award in 2015, recognizing her commitment to developing employees, and has received two Star of Excellence Awards.

Dr. Timothy Henry, MD, Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital discusses coronary microvascular dysfunction (CMD) a type of non-obstructive coronary artery disease that causes decreased blood flow to the heart muscle, affects the smallest arteries, and won't always show up on a regular exam. (The condition used to be called Syndrome X, and patients were assumed to be experiencing anxiety or a psychological issue rather than a cardiac one.) He talks about the warning signs and the developing treatment options in the space.

Garrett Bain, President of EcoGen BioSciences in Grand Junction, Colorado, discusses the increased demand for CBD therapeutics. He talks about the difference between hemp and cannabis and the associated therapeutics. He also talks about the withdrawal of the FDA's proposal to regulate the over-the-counter sales of CBD, and what this means to the industry. Garrett Bain, Chief Commercial Officer at Kadenwood and President of EcoGen BioSciences.Garrett is a trailblazer in the hemp and CBD space. He led sales and marketing for GenCanna from the early stages to one of the largest players in the global market – achieving revenue growth of over $100m in three years. His focus on integrating mainstream business practices into the hemp-derived CBD space helped to validate the industry and foster growth across multiple channels. Prior to hemp, Garrett was a VP of Sales in consumer goods distribution, servicing the global leaders of big box retail and ecommerce. His execution-oriented, “lead from the front” style, ca